Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).
Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J, Benseler V, Schnitzbauer AA, Hutchinson J, Deans R, Ladenheim D, Graveen CA, Zeman F, Koller M, Hoogduijn MJ, Geissler EK, Schlitt HJ, Dahlke MH.
Popp FC, et al. Among authors: zeman f.
J Transl Med. 2011 Jul 28;9:124. doi: 10.1186/1479-5876-9-124.
J Transl Med. 2011.
PMID: 21798013
Free PMC article.
Clinical Trial.